Of note, the expression of these markers was partially recovered in Nup153-treated AD organoids (Fig. 6A, WB optical density: DCX: C-GFP 1 ± 0.09, AD-GFP 0.15 ± 0.07, AD-Nup153-GFP 1.59 ± 0.14; β3Tub: C-GFP 1.00 ± 0.13, AD-GFP 0.22 ± 0.08, AD-Nup153-GFP 0.54 ± 0.03; MAP2: C-GFP 1.00 ± 0.31, AD-GFP 0.21 ± 0.08, AD-Nup153-GFP 0.48 ± 0.02; P < 0.05 ANOVA on RANKs followed by SKN test, n = 3; NF: C-GFP 1 ± 0.04, AD-GFP 0.49 ± 0.17, AD-Nup153-GFP 1.25 ± 0.17 P < 0.05 ANOVA followed by Bonferroni test, n = 3). The gene discussed is MAP2; the disease is Alzheimer disease.